Drug Trial Radar · NCT04694248
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
172
Planned (sponsor's estimate)
Start
Nov 3, 2021
Primary completion
Dec 31, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ningbo No.2 Hospital; Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University; The Central Hospital of Lishui City; Taizhou Enze Medical Center Group; Taizhou First People's Hospital; Boston Scientific Corporation
- First posted
- Jan 5, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of combination of anticoagulant and antiplatelet therapy on the patency of iliac vein at 12-month post stenting in patients with acute proximal DVT and ipsilateral iliac vein stenosis who received percutaneous mechanic thrombectomy and iliac vein stenting.
Conditions
- Deep Vein Thrombosis
- Iliac Vein Thrombosis
- Iliac Vein Obstruction
- Iliac Vein Stenosis
- Iliac Vein Compression Syndrome
Interventions
RivaroxabanDrug
For anticoagulant, it is rivaroxaban 20mg once a day for 6 months.
AspirinDrug
For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Effectiveness EndpointsTime frame: 12-month follow-up
- Primary Safety EndpointsTime frame: 12-month follow-up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affliated Hospital, Zhejiang University, School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.